Dupilumab in HIV-patient with atopic dermatitis: a case report

Atopic dermatitis is one of the most common diseases, occurring in 20 % of children in European countries and the USA, and in 7–14 % of adults according to various authors. The pathogenesis of atopic dermatitis is mainly based on the T2-associated type of the immune response. Various therapies are used, depending on the severity of AD. Targeted therapy is used for the treatment of moderate and severe atopic dermatitis, which is needed perform an assessment of possible contraindications to its administration. Among patients with HIV/AIDS has an increased incidence of atopic dermatitis, which is confirmed in serial studies. There is necessary to consider the pathogenetic mechanisms of the development of atopic dermatitis and HIV, to define rationally choice of the treatment for both atopic dermatitis and HIV. Modern treating methods of atopic dermatitis, which are selectively aimed at modeling T2-associated inflammation, have a relatively low risk of adverse events. One of these treatment methods is targeted therapy with biological drug dupilumab. Currently, there is limited scientific evidence for the effective use of dupilumab in patients with atopic dermatitis and HIV/AIDS.

The article presents a clinical case of severe atopic dermatitis in a HIV-patient, demonstrates the successful experience of using dupilumab over a long period of follow-up.